Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis

Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis

Background/Aim. Reslizumab is humanized monoclonal antibody produced by recombinant DNA technology which binds to circulating interleukin-5 (IL-5) and down-regulates the IL-5 signaling pathway. Reslizumab is indicated for the add-on maintenance treatment of patients 18 years and older with severe eo...

Full description

Bibliographic Details
Main Authors: Milosavljević Miloš N., Janković Slobodan M., Pejčić Ana V., Milovanović Jasmina R., Opančina Valentina D., Kostić Marina J.
Format: Article
Language:English
Published: Military Health Department, Ministry of Defance, Serbia 2018-01-01
Series:Vojnosanitetski Pregled
Subjects:
meta-analysis as topic
eosinophilia
anti-asthmatic agents
reslizumab
treatment outcome
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501700013M.pdf

Internet

http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501700013M.pdf

Similar Items